52 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
26359549	16	Cyclic Peptides Incorporating Phosphotyrosine Mimetics as Potent and Specific Inhibitors of the Grb7 Breast Cancer Target.	The University of Sydney
23182216	2	Novel inhibitors of a Grb2 SH3C domain interaction identified by a virtual screen.	University of Oxford
21381769	56	Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.	Universite£
19362470	17	Discovery of thioether-bridged cyclic pentapeptides binding to Grb2-SH2 domain with high affinity.	Chinese Academy of Sciences
18821748	24	Synthesis and utilization of chiral alpha-methylated alpha-amino acids with a carboxyalkyl side chain in the design of novel Grb2-SH2 peptide inhibitors free of phosphotyrosine.	Chinese Academy of Sciences
11931608	17	Inhibition of protein-protein association by small molecules: approaches and progress.	Pfizer
9873474	3	Actinomycin D, C2 and VII, inhibitors of Grb2-SHC interaction produced by Streptomyces.	Korea Research Institute of Bioscience and Biotechnology
21271718	6	Development of non-peptide ligands of growth factor receptor-bound protein 2-SRC homology 2 domain using molecular modeling and NMR spectroscopy.	Universidad Complutense De Madrid
19906464	2	Synthesis of aryl phosphates based on pyrimidine and triazine scaffolds.	Cnrs Umr 176
11000046	1	8-O-Methylsclerotiorinamine, antagonist of the Grb2-SH2 domain, isolated from Penicillium multicolor.	Korea Research Institute of Bioscience & Biotechnology
17371004	10	Examination of acylated 4-aminopiperidine-4-carboxylic acid residues in the phosphotyrosyl+1 position of Grb2 SH2 domain-binding tripeptides.	National Cancer Institute-Frederick
17113302	3	High affinity Grb2-SH3 domain ligand incorporating Cbeta-substituted prolines in a Sos-derived decapeptide.	Université
16908148	6	Application of azide-alkyne cycloaddition 'click chemistry' for the synthesis of Grb2 SH2 domain-binding macrocycles.	Nih
16509576	27	Discovery of a novel nonphosphorylated pentapeptide motif displaying high affinity for Grb2-SH2 domain by the utilization of 3'-substituted tyrosine derivatives.	Graduate School of The Chinese Academy of Sciences
16078854	4	Design and synthesis of 4-(alpha-hydroxymalonyl)phenylalanine as a new phosphotyrosyl mimetic and its use in growth factor receptor bound 2 src-homology 2 (Grb2 SH2) domain-binding peptides.	National Cancer Institute-Frederick
15943469	14	Examination of phosphoryl-mimicking functionalities within a macrocyclic Grb2 SH2 domain-binding platform.	National Cancer Institute-Frederick
15713392	3	Utilization of a nitrobenzoxadiazole (NBD) fluorophore in the design of a Grb2 SH2 domain-binding peptide mimetic.	Nih
15689160	7	Design and synthesis of conformationally constrained Grb2 SH2 domain binding peptides employing alpha-methylphenylalanyl based phosphotyrosyl mimetics.	National Cancer Institute-Frederick
15149676	7	Development of l-3-aminotyrosine suitably protected for the synthesis of a novel nonphosphorylated hexapeptide with low-nanomolar Grb2-SH2 domain-binding affinity.	Institute of Materia Medica
15056012	6	Macrocyclization in the design of non-phosphorus-containing Grb2 SH2 domain-binding ligands.	National Cancer Institute-Frederick
14761181	4	Synthesis of a 5-methylindolyl-containing macrocycle that displays ultrapotent Grb2 SH2 domain-binding affinity.	National Cancer Institute-Frederick
12801226	6	Utilization of a beta-aminophosphotyrosyl mimetic in the design and synthesis of macrocyclic Grb2 SH2 domain-binding peptides.	National Cancer Institute-Frederick
12798329	18	Potent Grb2-SH2 domain antagonists not relying on phosphotyrosine mimics.	National Cancer Institute-Frederick
12617916	13	Structure-based design of thioether-bridged cyclic phosphopeptides binding to Grb2-SH2 domain.	National Cancer Institute-Frederick
12519063	5	Macrocyclization in the design of Grb2 SH2 domain-binding ligands exhibiting high potency in whole-cell systems.	National Cancer Institute-Frederick
12217375	6	Development of a phosphatase-stable phosphotyrosyl mimetic suitably protected for the synthesis of high-affinity Grb2 SH2 domain-binding ligands.	National Institutes of Health
11459654	4	Macrocyclization in the design of a conformationally constrained Grb2 SH2 domain inhibitor.	National Institutes of Health
11354377	8	Convergent synthesis of potent peptide inhibitors of the Grb2-SH2 domain by palladium catalyzed coupling of a terminal alkyne.	Novartis Pharma
11055351	6	Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 1.	Novartis Pharmaceuticals
10853661	25	Examination of novel non-phosphorus-containing phosphotyrosyl mimetics against protein-tyrosine phosphatase-1B and demonstration of differential affinities toward Grb2 SH2 domains.	National Cancer Institute-Bethesda
10762050	4	Inhibition of the ras-dependent mitogenic pathway by phosphopeptide prodrugs with antiproliferative properties.	University of Paris
10715157	16	Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic.	National Cancer Institute-Bethesda
10571147	7	Mapping the X(+1) binding site of the Grb2-SH2 domain with alpha,alpha-disubstituted cyclic alpha-amino acids.	Novartis Pharma
10479306	14	Small peptides containing phosphotyrosine and adjacent alphaMe-phosphotyrosine or its mimetics as highly potent inhibitors of Grb2 SH2 domain.	University of Paris
10465559	8	Significant compensatory role of position Y-2 conferring high affinity to non-phosphorylated inhibitors of Grb2-SH2 domain.	National Cancer Institute-Bethesda
10450965	4	Structure-based design of a non-peptidic antagonist of the SH2 domain of GRB2.	Novartis Pharmaceuticals
10395476	3	Structure-based design, synthesis, and X-ray crystallography of a high-affinity antagonist of the Grb2-SH2 domain containing an asparagine mimetic.	Novartis Pharma
10091682	10	Monocarboxylic-based phosphotyrosyl mimetics in the design of GRB2 SH2 domain inhibitors.	National Cancer Institute-Bethesda
10090780	28	Structural and conformational requirements for high-affinity binding to the SH2 domain of Grb2(1).	Novartis Forschungsinstitut
10021933	11	Highly potent inhibitors of the Grb2-SH2 domain.	Novartis Pharma
9888830	14	Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands.	National Cancer Institute-Bethesda
9873638	6	Structure-based design of peptidomimetic ligands of the Grb2-SH2 domain.	Novartis Pharma
9719597	12	Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain.	Novartis Pharma
9599224	10	Potent antagonists of the SH2 domain of Grb2: optimization of the X+1 position of 3-amino-Z-Tyr(PO3H2)-X+1-Asn-NH2.	Novartis Pharma
9357522	6	Discovery of 3-aminobenzyloxycarbonyl as an N-terminal group conferring high affinity to the minimal phosphopeptide sequence recognized by the Grb2-SH2 domain.	Novartis Pharma
24856058	3	Protein-ligand interactions: probing the energetics of a putative cation-? interaction.	The University of Texas
7473554	7	L-O-(2-malonyl)tyrosine: a new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides.	National Cancer Institute-Bethesda
10072676	15	Acquisition of high-affinity, SH2-targeted ligands via a spatially focused library.	The Albert Einstein College of Medicine of Yeshiva University
15808463	35	Design, synthesis, and activity of achiral analogs of 2-quinolones and indoles as non-thiol farnesyltransferase inhibitors.	Abbott Laboratories
12443771	19	Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics.	Merck Research Laboratories